Belite Bio (NASDAQ:BLTE – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.02), Zacks reports.
Belite Bio Stock Up 0.5 %
NASDAQ:BLTE opened at $67.81 on Tuesday. The company’s 50 day moving average price is $58.58 and its 200-day moving average price is $60.47. Belite Bio has a 52 week low of $31.01 and a 52 week high of $86.53. The stock has a market cap of $2.16 billion, a price-to-earnings ratio of -61.09 and a beta of -1.54.
Analyst Upgrades and Downgrades
Separately, Benchmark boosted their price target on shares of Belite Bio from $57.00 to $79.00 and gave the company a “buy” rating in a research report on Tuesday, January 21st.
Belite Bio Company Profile
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.
See Also
- Five stocks we like better than Belite Bio
- What is Insider Trading? What You Can Learn from Insider Trading
- Taiwan Semiconductor Valuation: How Realistic Is the Price?
- How to Profit From Growth Investing
- Microsoft’s AI Strategy Eases Analyst Concerns—Is It a Buy?
- Best Aerospace Stocks Investing
- CrowdStrike Stock Attracts Congressional Buyers—Time to Invest?
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.
